Small molecules in targeted cancer therapy: advances, challenges, and future perspectives

Due to the advantages in efficacy and safety compared with traditional chemotherapy drugs, targeted therapeutic drugs have become mainstream cancer treatments. Since the first tyrosine kinase inhibitor imatinib was approved to enter the market by the US Food and Drug Administration (FDA) in 2001, an...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Signal Transduct Target Ther
Main Authors: Zhong, Lei, Li, Yueshan, Xiong, Liang, Wang, Wenjing, Wu, Ming, Yuan, Ting, Yang, Wei, Tian, Chenyu, Miao, Zhuang, Wang, Tianqi, Yang, Shengyong
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2021
Assuntos:
Review Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8165101/
https://ncbi.nlm.nih.gov/pubmed/34054126
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41392-021-00572-w
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados